JOURNAL BROWSE
Search
Advanced SearchSearch Tips
The Evolution and Value of Diphtheria Vaccine
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : KSBB Journal
  • Volume 26, Issue 6,  2011, pp.491-504
  • Publisher : Korean Society for Biotechnology and Bioengineering
  • DOI : 10.7841/ksbbj.2011.26.6.491
 Title & Authors
The Evolution and Value of Diphtheria Vaccine
Bae, Kyung-Dong;
  PDF(new window)
 Abstract
This review article provides an overview of the evolution of diphtheria vaccine, its value and its future. Diphtheria is an infectious illness caused by diphtheria toxin produced by pathogenic strains of Corynebacterium diphtheriae. It is characterized by a sore throat with membrane formation due to local tissue necrosis, which can lead to fatal airway obstruction; neural and cardiac damage are other common complications. Diphtheria vaccine was first brought to market in the 1920s, following the discovery that diphtheria toxin can be detoxified using formalin. However, conventional formalin-inactivated toxoid vaccines have some fundamental limitations. Innovative technologies and approaches with the potential to overcome these limitations are discussed in this paper. These include genetic inactivation of diphtheria toxoid, innovative vaccine delivery systems, new adjuvants (both TLR-independent and TLR-dependent adjuvants), and heat- and freeze-stable agents, as well as novel platforms for producing improved conventional vaccine, DNA vaccine, transcutaneous (microneedle-mediated) vaccine, oral vaccine and edible vaccine expressed in transgenic plants. These innovations target improvements in vaccine quality (efficacy, safety, stability and consistency), ease of use and/or thermal stability. Their successful development and use should help to increase global diphtheria vaccine coverage.
 Keywords
Diphtheria vaccine;TLR-dependent adjuvant;TLR-independent adjuvant;vaccine delivery system;DNA vaccine;heat-stable and freeze-stable agents;
 Language
English
 Cited by
1.
Bacterial toxin's DNA vaccine serves as a strategy for the treatment of cancer, infectious and autoimmune diseases, Microbial Pathogenesis, 2016, 100, 184  crossref(new windwow)
 References
1.
Akama, K., S. Kameyama, S. Otani, S. Sadahiro, and R. Murata (1971) Reversion of toxicity of diphtheria toxoid. Japanese Journal of Medical Science & Biology 24: 183-187. crossref(new window)

2.
Amorij, J. P., T. A. Westra, W. L. Hinrichs, A. Huckriede, and H. W. Frijlink (2007) Towards an oral influenza vaccine: comparison between intragastric and intracolonicdelivery of influenza subunit vaccine in a murine model. Vaccine 26: 67-76. crossref(new window)

3.
Anderson, D. G., W. Peng, A. Akinc, N. Hossain, A. Kohn, R. Padera, R. Langer, and J. A. Sawicki (2004) A polymer library approach to suicide gene therapy for cancer. Proceedings of the National Academy of Sciences of the United States of America 101: 16028-16033. crossref(new window)

4.
Anderson, P., J. Treanor, S. Porcelli, and M. Pichichero (2003) Non-interference between two protein carriers when used with the same polysaccharide for pneumococcal conjugate vaccines in 2-year-old children. Vaccine 21: 1554-1559. crossref(new window)

5.
Antoni, G., M. Bigio, G. Borri, M. C. Casagli, and P. Neri (1983) Purification of diphtheria toxin by chromatography on cibacron blue-sepharose. Experientia 39: 885-886. crossref(new window)

6.
Arya, S. C. (1994) Human immunization in developing countries: practical and theoretical problems and prospects. Vaccine 12: 1423-1435. crossref(new window)

7.
Atmar, R. L. and W. A. Keitel (2009) Adjuvants for pandemic influenza vaccines. Current Topics in Microbiology and Immunology 333: 323-344. crossref(new window)

8.
Bae, K., J. Choi, Y. Jang, S. Ahn, and B. Hur (2009) Innovative vaccine production technologies: the evolution and value of vaccine production technologies. Archives of Pharmacal Research 32: 465-480. crossref(new window)

9.
Bell, F., A. Martin, C. Blondeau, C. Thornton, J. Chaplais, and A. Finn (1996) Combined diphtheria, tetanus, pertussis, and Heamophilus influenzae type b vaccines for primary immunization. Archives of Disease in Childhood 75: 298-303. crossref(new window)

10.
Belsey, M. A. (1970) Isolation of Corynebacterium diphtheriae in the environment of skin carriers. American Journal of Epidemiology 91: 294-299.

11.
Botet Asensi, F. I., A. Veronese, M. Del Carmen Otero, M. Desamparados Tamarit Pérez, J. L. Hontangas Lopez, and S. Viviani (2003) Immunogenicity and safety in infants of a DTwPHib full liquid vaccine. Acta Paediatrica 92: 541-545. crossref(new window)

12.
Brandau, D. T., L. S. Jones, C. M. Wiethoff, J. Rexroad, and C. R. Middaugh (2003) Thermal stability of vaccines. Journal of Pharmaceutical Sciences 92: 218-231.

13.
Braun, L. J., A. Tyagi, S. Perkins, J. Carpenter, D. Sylvester, M. Guy, D. Kristensen, and D. Chen (2009) Development of a freeze-stable formulation for vaccine containing aluminum salt adjuvants. Vaccine 27: 72-79. crossref(new window)

14.
Buzzi, S., D. Rubboli, G. Buzzi, A. M. Buzzi, C. Morisi, and F. Pironi (2004) CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunology, Immunotherapy 53:1041-1048.

15.
Buzzi, S., G. Buzzi, A. M. Buzzi, and S. Martini (2007) CRM197: reduction of atherosclerotic stenoses in carotids of three elderly patients. Therapy 4: 293-298. crossref(new window)

16.
Carroll, S. F., J. T. Barbieri, and R. J. Collier (1988) Diphtheria toxin: purification and properties. Methods in Enzymology 165: 68-76. crossref(new window)

17.
Atkinson, W., J. Hamborsky, L. McIntyre, and S. Wolfe (2007) Epidemiology and Prevention of Vaccine-preventable Diseases (the pink book), 10th ed., pp. 59-70. Centers for Disease Control and Prevention, Public Health Foundation, Washington DC, USA.

18.
Cerdeno-Tarraga, A. M., A. Efstratiou, L. G. Dover, M. T. Holden, M. Pallen, S. D. Bentley, G. S. Besra, C. Churcher, K. D. James, A. De Zoysa, T. Chillingworth, A. Cronin, L. Dowd, T. Feltwell, N. Hamlin, S. Holroyd, K. Jagels, S. Moule, M. A. Quail, E. Rabbinowitsch, K. M. Rutherford, N. R. Thomson, L. Unwin, S. Whitehead, B. G. Barrell, and J. Parkhill (2003) The complete genome sequence and analysis of Corynebacterium diphtheriae NCTC13129. Nucleic Acids Research 31: 6516-6523. crossref(new window)

19.
Chen, D., C. A. Erickson, R. L. Endres, S. B. Periwal, Q. Chu, C. Shu, Y. F. Maa, and L. G. Payne (2001) Adjuvantation of epidermal powder immunization. Vaccine 19: 2908-2917. crossref(new window)

20.
Chen, D., A. Tyagi, J. Carpenter, S. Perkins, D. Sylvester, M. Guy, D. D. Kristensen, and L. J. Braun (2009) Characterization of the freeze sensitivity of a hepatitis B vaccine. Human Vaccines 5: 26-32. crossref(new window)

21.
Chen, W. C. And L. Huang (2005) Non-viral vector as vaccine carrier. Advances in Genetics 54: 315-337. crossref(new window)

22.
Chodaczek, G. (2004) Adjuvants as factors improving efficiency of vaccination. Postey higieny i medycyny doswiadczalnej 58: 47-59.

23.
Clausi, A., J. Cummiskey, S. Merkley, J. F. Carpenter, L. J. Braun, and T. W. Randolph (2008) Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. Journal of Pharmaceutical Sciences 97: 5252-5262. crossref(new window)

24.
Collier, R. J. (1975) Diphtheria toxin: mode of action and structure. Bacteriological Reviews 39: 54-85.

25.
Collier, R. J. (2001) Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century. Toxicon 39: 1793-1803. crossref(new window)

26.
Cooper, P. D. (1994) The Selective Induction of Different Immune Responses by Vaccine Adjuvants. pp. 125-158. In: G. L. Ada (eds.). Strategies in Vaccine Design, Landes, Austin, TX, USA.

27.
Corbel, M. J. (1996) Reasons for instability of bacterial vaccines. Developments in Biological Standardization 87: 113-124.

28.
Crane, D. T., B. Bolgiano, and C. Jones (1997) Comparison of the diphtheria mutant toxin, CRM197, with a Haemophilus influenzae type-b polysaccharide-CRM197 conjugate by optical spectroscopy. European Journal of Biochemistry 246: 320-327. crossref(new window)

29.
Crosbie, W. E. and H. D. Wright (1941) Diphtheria bacilli in floor dust. Lancet 237: 656-659. crossref(new window)

30.
Danilova, E., A. Shiryayev, V. Skogen, E. K. Kristoffersen, and H. Sjursen (2005) Short-term booster effect of diphtheria toxoid in initially long-term protected individuals. Vaccine 23: 1446-1450. crossref(new window)

31.
Deeks, E. D. (2010) Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults. Bio. Drugs 24: 287-297.

32.
Del Giudice, G., M. Pizza, and R. Rappuoli (1998) Molecular basis of vaccination. Molecular Aspects of Medicine 19: 1-70. crossref(new window)

33.
Ding, Z., S. M. Bal, S. Romeijn, G. F. Kersten,W. Jiskoot, and Bouwstra (2011) Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array. Pharmaceutical Research 28: 145-158. crossref(new window)

34.
Ding, Z., E. Van Riet, S. Romeijn, G. F. Kersten, W. Jiskoot, and J. A. Bouwstra (2009) Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharmaceutical Research 26: 1635-1643. crossref(new window)

35.
Efstratiou, A. and R. C. George (1999) Laboratory guidelines for the diagnosis of infections caused by Corynebacterium diphtheriae and C. ulcerans. Communicable Disease and Public Health 2: 250-257.

36.
Efstratiou, A., K. H. Engler, and A. De Zoysa (1998) Diagnosis and epidemiology of diphtheria. Methods in Molecular Medicine 15: 191-212.

37.
Eldridge, J. H., R. M. Gilley, J. K. Staas, Z. Moldoveanu, J. A. Meulbroek, and T. R. Tice (1989) Biodegradable microspheres: vaccine delivery system for oral immunization. Current Topics in Microbiology and Immunology 146: 59-66. crossref(new window)

38.
El Sahly, H. (2010) $MR59^{TM}$ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Review of Vaccines 9: 1135-1141. crossref(new window)

39.
Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, P., R. Kohberger, G. Siber, and P. H. Makela (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. The New England Journal of Medicine 344: 403-409. crossref(new window)

40.
Felnerova, D., J. F. Viret, R. Gluck, and C. Moser (2004) Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Current Opinion in Biotechnology 15: 518-529. crossref(new window)

41.
Flebbe, L. M. and H. Braley-Mullen (1986) Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens. Cellular Immunology 99: 119-127. crossref(new window)

42.
Fratelli, F., J. Abrahao-Neto, A. T. Caricati, M. M. Borges, R. Guidolin, and C. P. Caricati (2011) An alternative method for purifying and detoxifying diphtheria toxin. Toxicon 57: 1093-1100. crossref(new window)

43.
Galazka, A., J. Milstien, and M. Zaffran (1998) Thermostability of vaccines, World Health Organization, Geneva. Switzerland.

44.
Garcon, N., P. Chomez, and M. Van Mechelen (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Review of Vaccines 6: 723-739. crossref(new window)

45.
Gardner, P. (2001) Issues related to the decennial tetanusdiphtheria toxoid booster recommendations in adults. Infectious Disease and Clinics of North America 15: 143-153. crossref(new window)

46.
Giannini, G., R. Rappuoli, and R. Ratti (1984) The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Research 12: 4063-4069. crossref(new window)

47.
Glenny, A. T. and H. J. Sudmersen (1921) Notes on the production of immunity to diphtheria toxin. The Journal of Hygiene 20: 176-220. crossref(new window)

48.
Godefroy, S., M. Peyre, N. Garcia, S. Muller, D. Sesardic, and C. D. Partidos (2005) Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197) of diphtheria toxin. Infection and Immunity 73: 4803-4809. crossref(new window)

49.
Grabenstein, J. D. (2010) Toxoid Vaccines, pp. 105-124. In: A. W. Artenstein (eds.). Vaccines: A Biography. Springer, NY, USA.

50.
Gupta, R. K., R. J. Collier, R. Rappuoli, and G. R. Siber (1997) Differences in the immunogenicity of native and formalinized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs. Vaccine 15: 1341-1343. crossref(new window)

51.
Gurunathan, S., C. Y. Wu, B. L. Freidag, and R. A. Seder (2000) DNA vaccines: a key for inducing long-term cellular immunity. Current Opinion in Immunology 12: 442-447. crossref(new window)

52.
Hadfield, T. L., P. McEvoy, Y. Polotsky, V. A. Tzinserling, and A. A. Yakovlev (2000) The pathology of diphtheria. The Journal of Infectious Diseases 181: S116-S120. crossref(new window)

53.
Havaldar, P. V., M. N. Sankpal, and R. P. Doddannavar (2000) Diphtheritic myocarditis: clinical and laboratory parameters of prognosis and fatal outcome. Annals of Tropical Paediatrics 20: 209-215.

54.
Higashiyama, S., R. Iwamoto, K. Goishi, G. Raab, N. Taniguchi, M. Klagsbrun, and Mekada (1995) The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. The Journal of Cell Biology 128: 929-938. crossref(new window)

55.
Holmes, R. K. (2000) Biology and molecular epidemiology of diphtheria toxin and the tox gene. The Journal of Infectious 181: S156-S167. crossref(new window)

56.
Honjo, T., Y. Nishizuka, and O. Hayashi (1968) Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis. The Journal of Biological Chemistry 243: 3553-3555.

57.
Iwamoto, R., S. Higashiyama, T. Mitamura, N. Taniguchi, M. Klagsbrun, and E. Mekada (1994) Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulatesfunctional receptors and diphtheria toxin sensitivity. The EMBO Journal 13: 2322-2330.

58.
Jezek, J., D. Chen, L. Watson, J. Crawford, S. Perkins, A. Tyagi, and Jones-Braun (2009) A heat-stable hepatitis B vaccine formulation. Human Vaccines 5: 529-535. crossref(new window)

59.
Johasen, P., L. Moon, H. Tamber, H. P. Merkle, B. Gander, and D. Sesardic (1999) Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 18: 209-215. crossref(new window)

60.
Johnson, V. G., D. Wilson, L. Greenfield, and R. J. Youle (1988) The role of the diphtheria toxin receptor in cytosol translocation. The Journal of Biological Chemistry 263: 1295-1300.

61.
Johnson, V. G. and R. J. Youle (1989) A point mutation of proline 308 in diphtheria toxin B chain inhibits membrane translocation of toxin conjugates. The Journal of Biological Chemistry 264: 17739-17744.

62.
Jones, E. E., R. J. Kim-Farley, M. Algunaid, M. A. Parvez, Y. A. Ballad, A. W. Hightower, W. A. Orenstein, and C. V. Broome (1985) Diphtheria: a possible foodborne outbreak in hodeida and yemen arab republic. Bulletin of the World Health Organization 63: 287-293.

63.
Kaczorek, M., F. Delpeyroux, N. Chenciner, R. E. Streeck, J. R. Murphy, P. Boquet, and P. Tiollais (1983) Nucleotide sequence and expression of the diphtheria tox228 gene in Escherichia coli. Science 221: 855-858. crossref(new window)

64.
Kageyama, T., M. Ohishi, S. Miyamoto, H. Mizushima, R. Iwamoto, and E. Mekada (2007) Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. Journal of Biochemistry 142: 95-104. crossref(new window)

65.
Kaistha, J., J. Sokhey, S. Singh, S. Kumar, P. C. John, and N. C. Sharma (1996) Adjuvant effect of DEAE-dextran and tetanus toxoid on whole cell heat inactivated phenol preserved typhoid vaccine. Indian Journal of Pathology & Microbiology 39: 287-292.

66.
Latz, E., A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, E. Lien, N. J. Nilsen, T. Espevik, and D. T. Golenbock (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nature Immunology 5: 190-198. crossref(new window)

67.
Lowenstein, E. (1909) Uber aktive schutzimpfung bei tetanus durch toxoide. Z. Hyg. InfektKr. 62: 491-508. crossref(new window)

68.
Maa, Y. F., L. Zhao, L. G. Payne, and D. Chen (2003) Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. Journal of Pharmaceutical Sciences 92: 319-332. crossref(new window)

69.
Matjila, M. J., T. C. Phohu, A. Banzhoff, S. Viviani, A. A. Hoosen, M. Bianchini, P. Nacci, C. W. Palweni, Podda, A., M. Whitfield, and S. Aspinall (2004) Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines. South African Medical journal 94: 43-46.

70.
Mattos-Guaraldi, A. L., L. O. Moreira, P. V. Damasco, and R. Hirata Junior (2003) Diphtheria remains a threat to health in the developing world - an overview. Memorias do Instituto Oswaldo Cruz 98: 987-993. crossref(new window)

71.
Maxwell, F., I. H. Maxwell, and L. M. Glode (1987) Cloning, sequence determination, and expression in transfected cells of the coding sequence for the tox 176 attenuated diphtheria toxin A chain. Molecular and Cellular Biology 7: 1576-1579.

72.
McCluskie, M. J., R. D. Weeratna, A. M. Krieg, and H. L. Davis (2000) CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19: 950-957. crossref(new window)

73.
McNeela, E. A., I. Jabbal-Gill, L. Illum, M. Pizza, R. Rappuoli, A. Podda, D. J. Lewis, and K. H. Mills (2004) Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22: 909-914. crossref(new window)

74.
McNeela, E. A., D. O'Connor, I. Jabbal-Gill, L. Illum, S. S. Davis, M. Pizza, S. Peppoloni, R. Rappuoli, and K. H. Mills (2000) A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19: 9-10. crossref(new window)

75.
Metz, B., W. Jiskoot, W. E. Hennink, D. J. Crommelin, and G. F. Kersten (2003) Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccine. Vaccine 22: 156-167. crossref(new window)

76.
Metz, B., G. F. Kersten, P. Hoogerhout, H. F. Brugghe, H. A. Timmermans, A. de Jong, H. Meiring, J. ten Hove, W. E. Hennink, D. J. Crommelin, and W. Jiskoot (2004) Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. The Journal of Biological Chemistry 279: 6235-6243.

77.
Micoli, F., S. Rondini, I. Pisoni, D. Proietti, F. Berti, F. Costantino, R. Rappuoli, S. Szu, A. Saul, and L. B. Martin (2011) Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 29: 712-720. crossref(new window)

78.
Middaugh, J. P. (1979) Side-effects of diphtheria-tetaneus toxoid in adults. American Journal of Public Health 69: 246-249. crossref(new window)

79.
Mills, K. H., C. Cosgrove, E. A. McNeela, A. Sexton, R. Giemza, I. Jabbal-Gill, A. Church, W. Lin, L. Illum, and A. Podda (2003) Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin. Infection and Immunity 71: 726-732. crossref(new window)

80.
Milstien, J. B., S. M. Lemon, and P. F. Wright (1997) Development of a more thermostable poliovirus vaccine. The Journal of Infectious Disease 175: S247-S253. crossref(new window)

81.
Mitamura, T., T. Umata, F. Nakano, Y. Shishido, T. Toyoda, A. Itai, H. Kimura, and E. Mekada (1997) Structure-function analysis of the diphtheria toxin receptor toxin binding site by site-directed mutagenensis. The Journal of Biological Chemistry 272: 27084-27090. crossref(new window)

82.
Mokrousov, I. (2009) Corynebacterium diphtheriae: genome diversity, population structure and genotyping perspectives. Infection, Genetics and Evolution 9: 1-15. crossref(new window)

83.
Moreira, L. de O., A. F. Andrade, M. D. Vale, S. M. Souza, R. Jr. Hirata, L. M. Asad, N. R. Asad, L. H. Monteiro-Leal, J. O. Previato, and A. L. Mattos-Guaraldi (2003) Effects of iron limitation on adherence and cell surface carbohydrates of Corynebacterium diphtheriae strains. Applied and Environmental Microbiology 69: 5907-5913. crossref(new window)

84.
Morris, R. E., A. S. Gerstein, P. F. Bonventre, and C. B. Saelinger (1985) Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infection and Immunity 50: 721-727.

85.
Mortimer, E. A. (1988) Diphtheria toxoid. pp. 31-44. In: S. A. Plotkin and E. A. Jr. Mortimer (eds.). Vaccines. W. B. Saunders Company. Philadelphia, USA.

86.
Moyner, K. and G. Christiansen (1984) Comparison of gel filtration and ammonium sulphate precipitation in the purification of diphtheria toxin and toxoid, Acta pathologica, microbiologica, et immunologica Scandinavica, Immunology 92: 17-23.

87.
Murdan, S., S. Somavarapu, A. C. Ross, H. O. Alpar, and M. C. Parker (2005) Immobilisation of vaccines onto micro-crystals for enhanced thermal stability. International Journal of Pharmaceutics 296: 117-121. crossref(new window)

88.
Murphy, J. R. (2011) Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. Toxin 3: 294-308. crossref(new window)

89.
Muttil, P., B. Pulliam, L. Garcia-Contreras, J. K. Fallon, C. Wang, A. J. Hickey, and D. A. Edwards (2010) Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. The AAPS journal 12: 699-707. crossref(new window)

90.
Naglich, J. G., J. E. Metherall, D. W. Russell, and L. Eidels (1992) Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69: 1051-1061. crossref(new window)

91.
Pappenheimer, A. M. Jr (1977) Diphtheria toxin. Annual Review of Biochemistry 46: 69-94. crossref(new window)

92.
Peek, L. J., C. R. Middaugh, and C. Berkland (2001) Nanotechnology in vaccine delivery. Advanced Drug Delivery Reviews 60: 915-928.

93.
Petre, J., M. Pizza, L. Nencioni, A. Podda, M. T. De Magistris, and R. Rappuoli (1996) The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. Developments in Biological Standardization 87: 125-134.

94.
Pizza, M., M. R. Fontana, V. Scarlato, and R. Rappuoli (1996) Genetic detoxification of bacterial toxins. Methods in Molecular Medicine 4: 91-109.

95.
Pope, C. G. (1963) Development of knowledge of antitoxins. British Medical Bulletin 19: 230-234.

96.
Popovic, T., I. K. Mazurova, A. Efstratiou, J. Vuopio-Varkila, M. W. Reeves, A. De Zoysa, T. Glushkevich, and P. Grimont (2000) Molecular epidemiology of diphtheria. The Journal of Infectious Disease 181: S168-S177. crossref(new window)

97.
Porro, M., M. Saletti, L. Nencioni, L. Tagliaferri, and I. Marsili (1980) Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid. The Journal of Infectious Disease 142: 716-724. crossref(new window)

98.
Qiao, J., K. Ghani, and M. Caruso (2008) Diphtheria toxin mutant CRM 197 is an inhibitor of protein synthesis that induces cellular toxicity. Toxicon 51: 473-477. crossref(new window)

99.
Qureshi, N., P. Mascagni, E. Ribi, and K. Takayama (1985) Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595: purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. The Journal of Biological Chemistry 260: 5271-5278.